MRNA close to buyI think 20$ is a good support to buy MRNA. It gave 100% of the covid gains back.
Base - Rally - Base pattern
MRNA trade ideas
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MRNA Shares Drop?
On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade.
During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy.
However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.”
The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration.
Technical Analysis of MRNA Shares
The chart indicates that:
➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average).
➝ Over the past five months, it has been forming a descending channel (marked in red).
➝ The lower boundary of this channel acted as support yesterday.
The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism.
It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine'It's gone 5 years or so... (Duh..? 5 years, really? 🥴) since everyone was talking about COVID-19 pandemic, vaccines, "world will never be the same again", and so on.
- And now?..
- It's gone. It's absolutely gone..! Since nothing last forever and no one should chase a feather, or dust in the wind.
This is why we at our 💖Super-Duper Beloved @PandorraResearch Team decided to build this idea, as a educational idea to learn, even this story is about single Moderna stock, and we have reasonable considerations about fundamental, technical and price movement perspectives.
Well.. Let's the story begin...
Over the past few years, Moderna's stock has experienced a significant decline, primarily due to several key factors.
Here's a detailed explanation of why Moderna's stock has been moving downward:
1. Declining Demand for COVID-19 Vaccine
The primary reason for Moderna's stock decline is the waning demand for COVID-19 vaccines. During the pandemic, Moderna's mRNA-based vaccine was one of the first and most widely used, leading to a surge in sales and profitability. However, as the pandemic transitioned into an endemic phase, demand for vaccines decreased substantially. This shift has resulted in declining sales for Moderna, impacting its revenue and profitability.
2. Sales Guidance and Performance
In recent years, Moderna has faced challenges in meeting sales expectations. For instance, in 2025, the company forecasted sales between $1.5 billion and $2.5 billion, which was significantly lower than analysts' expectations of around $2.9 billion. This discrepancy led to a sharp decline in stock prices as investors became increasingly pessimistic about the company's future growth prospects.
3. Cost-Cutting Measures
To mitigate the impact of declining sales, Moderna has implemented cost-cutting measures. The company plans to reduce its cash operating costs by $1 billion in 2025 and an additional $500 million in 2026. While these efforts aim to improve profitability, they also reflect the challenges Moderna faces in maintaining its financial health without strong vaccine sales.
4. Competition in New Market s
Moderna is expanding into new markets, such as the respiratory syncytial virus (RSV) vaccine space, with its product mResvia. However, this market is highly competitive, with established players like Pfizer and GSK already present. The competition and uncertainty about market share have contributed to investor skepticism about Moderna's ability to drive growth through new products.
5. Delayed Break-Even Point
Initially, Moderna aimed to break even on an operating cash cost basis by 2026. However, this goal has been pushed back to 2028, indicating a slower-than-expected transition to profitability. This delay has further eroded investor confidence in the company's ability to execute its strategic plans effectively.
6. Valuation and Market Performance
Moderna's stock has underperformed both the industry and the broader market. The stock trades below its 200-day and 50-day moving averages, reflecting a lack of momentum. Additionally, Moderna's price-to-sales ratio is lower than the industry average, which might suggest undervaluation but also indicates a lack of investor enthusiasm for the stock.
7. Analyst Sentiment and Profitability Forecasts
Analysts have become increasingly pessimistic about Moderna's prospects, with many not expecting the company to turn profitable again until at least 2029. This negative outlook has contributed to the downward pressure on the stock. Furthermore, estimates for loss per share have increased, reinforcing the bearish sentiment among investors.
In summary, Moderna's stock decline is primarily driven by declining vaccine demand, missed sales expectations, increased competition in new markets, delayed profitability, and negative analyst sentiment. While the company is taking steps to adapt to these challenges, the path to recovery remains uncertain, contributing to ongoing investor skepticism.
--
Best 'No more Covid' wishes,
@PandorraResearch Team 😎
$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9)
Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble?
CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍
(2/9) – PRICE PERFORMANCE 📊
• Current Trend: Up 9% after CEO’s $5M buy on Mar 5, 2025 💰
• Context: Biotech’s a rollercoaster—posts on X show optimism 📈
• Sector Vibe: Volatile, but insider faith lifts spirits 🌈
It’s a wild climb—buckle up! ⚡
(3/9) – MARKET POSITION 📈
• Market Cap: Around $12B (based on 384M shares, est.) 🏅
• Operations: mRNA pioneer, vaccines to cancer therapies ⏳
• Trend: CEO’s move signals undervaluation hope 🎯
Solid player in the biotech jungle! 🌋
(4/9) – KEY DEVELOPMENTS 🔑
• Insider Buying: CEO’s $5M grab on Mar 5, 2025 🔄
• Buzz: Posts on X tie surge to leadership confidence 🌐
• Reaction: Market cheers, up 9% in a blink 📣
Risin’ like dough in a warm oven! 🔥
(5/9) – RISKS IN FOCUS ⚠️
• Volatility: Biotech swings wild amid macro uncertainty 🔎
• Policy: Healthcare shifts could sting 📉
• Pipeline: New products unproven, per X chatter 🌬️
High stakes, high drama! 🎭
(6/9) – SWOT: STRENGTHS 💪
• Innovation: mRNA tech reshapes medicine 🏆
• Confidence: CEO’s $5M bet screams belief 📊
• Legacy: COVID vaccine king, still swinging ⚒️
A biotech beast with bite! 🐺
(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️
• Weaknesses: Volatility, macro jitters hit hard 📉
• Opportunities: New mRNA goodies, partnerships loom 📈
Can it brew more magic or fizzle out? 🧪
(8/9) – 📢 Stock up 9% after CEO’s $5M buy—your call? 🗳️
#
• Bullish: $50+ soon, biotech boom 🚀
• Neutral: Holding steady, risks weigh ⚖️
• Bearish: $25 looms, bubble bursts 🐻#
Drop your vote below! 👇
(9/9) – FINAL TAKEAWAY 🎯
Moderna’s 9% pop on insider buying hints at hidden gems 📈, but biotech’s a stormy sea 🌊. Dips are our playground—DCA heaven 💸. Snag ‘em cheap, ride the wave! Winner or wild card?
MRNA'Ticker: MRNA
Direction: Up
Prognosis: Buy Calls (Author bought $40 and $41 calls expiring this week, considering rolling to later dates)
Reasoning: New Covid-like virus discovered, rising avian flu concerns, large institutional buying, bullish technical indicators (RSI divergence, MACD turning up), high call option volume and open interest. Author acknowledges that a drop below $30 could invalidate the thesis.
Disclaimer: This is not financial advice. MRNA is volatile; know your risk tolerance.
Bonus: Author also mentions potential plays on HD puts, LOW puts, and CLF calls.'
MRNA SL-$30,95 TP-$33Technical Analysis:
Weakness in bearish candles
Increase in volume may indicate a reversal
Engulfing candle on the daily chart
A reversal towards the mean on the H4 chart is likely
MACD on H4 indicates a probable inflection point
Strength on MRNADespite negative news, Moderna, Inc. stock is in a good position to rally. Its price has been falling since August 2021, but relatively big buys have begun to emerge since August 2024.
It has to be noted that on every bar with buying, volume is increasing, which is usually a sign of accumulation on a down move.
If the price breaks the $40.83 level (the high of the bar with the largest volume), then tests it on low volume later, and supply does not re-emerge in the $49.94 - $56.70 zone, this would signal the end of accumulation. In such a case, we could expect the move towards $102.90 - $118.10, and if shares would not be sold off there, it might go even higher to $156.94 - $163.19.
At the same time, if accumulation has not been finished yet, we may still see another leg down for more buying.
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment among investors.
Weighing the Challenges and Opportunities
On Friday, Moderna disclosed a Q4 2024 revenue of $966 million, marking a sharp 65% year-over-year decline. The loss per share stood at $2.91, exceeding the analyst projection of $2.73 per share. More concerning for investors was the company’s forecast for 2025 sales, estimated between $1.5 billion and $2.5 billion—significantly below the $3.26 billion consensus estimate.
CEO Stéphane Bancel reaffirmed Moderna’s focus on cutting costs and streamlining its research and development (R&D) efforts. The company plans to reduce R&D expenses by up to $1.1 billion by 2027, primarily by halting early-stage projects and prioritizing late-stage drug approvals. Moderna has already trimmed $1 billion in costs, positioning itself for leaner operations in the coming years.
Technical Analysis: Key Levels to Watch
From a technical perspective, NASDAQ:MRNA shares closed Friday’s session down 0.38%, showing hesitation despite the broader market’s strength. The stock is currently hovering near a critical support zone—the one-month low. Should this level fail to hold, a further decline towards the $25 region could be the next stop.
On the upside, a breakout above the 38.2% Fibonacci retracement level could alter the trajectory for Moderna’s stock, potentially signaling a bullish reversal. However, with the Relative Strength Index (RSI) at 41.46, the stock remains in weak momentum territory, suggesting that bullish conviction is still lacking.
Outlook: Can Moderna Reignite Investor Confidence?
Moderna’s near-term outlook remains uncertain, as the company grapples with declining COVID vaccine sales, weaker-than-expected 2025 revenue projections, and an ongoing shift in its R&D strategy. However, its pipeline of combination vaccines and upcoming approvals may offer a longer-term upside if execution is successful.
Technically, NASDAQ:MRNA needs to hold its key support zone and break above the 38.2% Fibonacci retracement to shift market sentiment positively. Until then, investors should watch for further signals of strength, particularly in trading volume and RSI movement, before confirming a potential bullish turnaround.
In the coming months, all eyes will be on Moderna’s next earnings report and the market’s reaction to its cost-cutting measures and pipeline advancements. The stock’s ability to sustain recent gains—or break lower—will depend on whether the company can deliver on its strategic shifts and stabilize its revenue trajectory.
MRNA Moderna Options Ahead of EarningsIf you haven`t bought MRNA before the previous earnings:
Now analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 45usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $3.65.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
$MRNA yieahhhrough day for some, good day for my DCA friends.
NASDAQ:MRNA on a rough down trend since covid days. Looking for a wild bounce here.
1. MACD curving to the upside
2. RSI Curving to the upside
3. Price is at the bottom of the parallel channel.
My bets are on seeing $60-$70 which is middle of the channel by the summer. Of course I bought some time.
Would be insane to see this going to $120 top of channel by eoy right? Maybe too insane?
Yieaahhh
12R Moderna LongExpecting a move up to the red supply zone.
Approx target 100, but being conservative by going shy of that.
There is strong confluence with other biotech companies here with many others also looking bullish for the following weeks.
MRNA - short term profit targets $46 - $49MRNA - short term profit targets $46 - $49
17K call options at strike $41.5 expiring 31 Jan
17K PuT options at strike $40 expiring 21 Mar
Bottom is behind us Moderna has gone through panic selling which tells me a generational bottom has probably formed.
Will MRNA rotate? CVS, UNH, JNJ all rotating in q1 of 2025. Will MRNA start to roll over and complete the weekly harmonic pattern and go for the TYPE 1 cycle? Long hold but seems like a no brainer. 🥂
Bird Flu - Short Squeeze incoming?Strong downtrend, ABC correction with the final C wave possibly in. Potential for a short squeeze as Moderna receives funding to develop a Bird Flu vaccine for the ongoing outbreak.
The financials don’t look great, this would be a short term trade with a tight stop loss.
Not financial advice, just a trade idea.
$MRNA to $90-115 | 100-150% upside in FY 2025- NASDAQ:MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco.
- This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
$MRNA has 50-100% upside from $43 in FY 2025- NASDAQ:MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research.
- NASDAQ:MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term.
- In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year.
- Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
Moderna Bullish Outlook With a broken Resistance , an oversold RSI and a beautiful oversold MFI , we anticipate MRNA to rise to the top of the descending and potential top of bull flag formation at $125.00 in the near term
- 160% ROI from $48.00 to $125.00
Moderna (MRNA) Down 92% from All-Time High – What's Next?Overview:
Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower?
Key Insights:
Support Levels:
Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area.
Catalysts to Watch:
Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
The Share Price of Moderna (MRNA) Surged Over 10% in a DayThe Share Price of Moderna (MRNA) Surged Over 10% in a Day
As shown by the chart of pharmaceutical company Moderna (MRNA):
→ 2024 was an extremely difficult year, with the price falling by approximately 60%;
→ however, in early 2025, we can see signs of renewed strength.
During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America.
This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials.
Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action.
Additionally:
→ there has been a breakout above the descending trend channel that dominated the end of 2024;
→ it is possible that price movements may form a new ascending channel (shown in blue);
→ further growth may be hindered by the psychological resistance level of $50.
According to TipRanks, analysts remain cautious about Moderna’s prospects:
→ only 4 out of 19 analysts recommend buying MRNA shares;
→ the average 12-month price target for MRNA is $62.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Halftime Update: MRNA - Moderna AnalysisMRNA is currently retesting a pivotal level of resistance that we believe could provide a greater push back to those higher $58.55 Price Levels as long as it can keep this momentum that it has, seeing a very large volume spike in this morning. If not, we would expect some consolidation back to $45.42 levels before pushing higher.
Stock jumped this morning after reporting a potential vaccine to combat the recent H5N1 Bird Flu. This comes after the first human death due to the Bird Flu in Louisiana, although the patient did have pre-existing medical conditions that contributed to the death, not to stir any feathers.
Don't really have a price projection or entry specifically for this as we're watching. This could pull back to those EMAs before gaining True Momentum Northward.
Connect with us by visiting the website below in our signature to get even more at @MyMIWallet
#MyMIWallet
Is Risk in your DNA?I hope to get perspective from others looking at this company. Is this whole sector with pharmacy overlooked? CVS poses as a play in brand? I am no marketing expert.
Moderna and the HMPV Virus: Your Thoughts?
Hi everyone
What are your views on Moderna following news of the dangerous HMPV virus in China? With Moderna already having a vaccine for HMPV, this could lead to significant orders from various countries.
Could this be a major growth opportunity for the company?
